Juzina

Sitagliptin, the active ingredient in Juzina, is a DPP‑4 inhibitor presented as an oral dosage form for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is indicated for the management of type 2 diabetes, acting on the incretin pathway to regulate blood glucose.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels when used alone or with other antidiabetic agents. - Combination therapy with metformin: provides additional HbA1c reduction compared with metformin monotherapy. - Adjunct to diet and exercise: helps patients achieve glycaemic targets when lifestyle measures are insufficient.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: cough, sore throat. - Gastrointestinal upset: nausea, abdominal discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia, sometimes persistent. - Bullous pemphigoid: rare skin blistering disorder. - Hypoglycaemia: particularly when combined with insulin or sulfonylureas.

Before initiating sitagliptin therapy, consider the following safety points.

- Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic impairment: use with caution in patients with moderate liver disease. - Cardiovascular disease: assess risk, especially in patients with a history of heart failure. - Pregnancy: category B; discuss potential benefits and risks with a healthcare professional. - Elderly patients: start at the lowest effective dose and monitor for adverse events. - Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in the original packaging.

Sitagliptin may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Concomitant insulin therapy: increased risk of hypoglycaemia. - Sulfonylureas (e.g., glipizide): heightened hypoglycaemia potential.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may affect renal clearance of sitagliptin. - ACE inhibitors (e.g., enalapril): monitor blood pressure and renal function. - Rifampin: enzyme induction may reduce sitagliptin plasma levels. - NSAIDs (e.g., ibuprofen): watch for renal function changes in susceptible patients.